The Leavitt alone approach

President Bush's appointment of Michael Leavitt as secretary of HHS reflects the administration's enthusiasm for avoiding political risk, rather than an interest in promoting specific agendas. The decision to pass over CMS Administrator Mark McClellan for the top HHS post suggests that the industry's concerns are not likely to be high on the agenda of the second Bush administration. It also amplifies the consequences of the leadership vacuum at FDA.

There is a strong sense among biotech executives that the failure to appoint McClellan to HHS represents an enormous missed opportunity. The hope was that he would integrate the HHS components and focus them

Read the full 1030 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE